Picoplatin

DB04874InvestigationalSmall molecule

Picoplatin is a cytotoxic platinum compound in clinical development for the treatment of patients with solid tumors. It causes apoptosis (cell death) by binding to DNA and interfering with DNA...

Mechanism: Picoplatin causes apoptosis (cell death) by binding to DNA and interfering with DNA replication and transcription.
Curator reviewed
Primary indication: For the treatment of patients with solid tumors.Curator reviewed
Formula / weight: C₆H₁₀Cl₂N₂Pt · 376.147 g/mol (avg)
Code names: AMD-473 · NX-473 · ZD-0473

Resolves to

Compound

UNIIB5TAN0L720CAS181630-15-9PubChem177358

Structure

InChIKeyIIMIOEBMYPRQGU-UHFFFAOYSA-LSMILESN.[Cl-].[Cl-].[Pt++].CC1=CC=CC=N1

What you can answer from here — as of January 14, 2023

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which companies are running trials of Picoplatin, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account